

# Weekly COVID-19 Breakthrough Infections Report

**Clark County, Nevada** 


## Date: January 17, 2023

Breakthrough cases are U.S. residents with a SARS-CoV2 RNA or antigen detected on respiratory specimen collected greater than or equal to 14 days after completing the primary series of an FDA authorized COVID-19 vaccine (i.e., complete vaccination). Complete vaccination is two doses of the Pfizer or Moderna vaccine or one dose of the Johnson and Johnson (Janssen) vaccine.


Exclusion Criteria: The persons who were recently positive for COVID-19, defined as a positive <45 days prior to the current positive test under investigations were excluded.


Given the large number of people being vaccinated in the United States and the high level of ongoing SARS-CoV-2 circulation, thousands of symptomatic vaccine breakthrough cases are expected, even if the vaccines remain as effective as demonstrated during the clinical trials.

Following data have been obtained by matching COVID-19 cases information from Trisano (SNHD's surveillance system) to immunization records from Nevada WebIZ (Immunization database). Data is considered preliminary and subject to change.



## Figure 1:Trends in Breakthrough Cases, Deaths and Hospitalizations







	Overall			
A 11	N %			
All	128656 10	U		
Age (in years)	-	~		
0-4	-	0		
5-11	1552	1		
12-17		5		
18-24		9		
25-49	56241 4			
50-64	30626 2			
65+ Cander	23293 1	ð		
Gender	50005 4			
Male	56065 4			
Female	71622 5			
Unknown	969	1		
Race/Ethnicity	00445 0			
Hispanic	26445 2			
White	40869 3			
Black		8		
API	16408 1	Ŭ		
AEA		0		
Other		7		
Unknown	25237 2	U		
Travel History				
Yes		4		
No	34784 2			
Unknown	88347 6	9		
Hospitalization		_		
Yes		3		
No	39225 3			
Unknown	86156 6	7		
Death				
Yes	1180	1		
No		8		
Unknown	117762 9	2		
Vaccine Type				
Pfizer	85995 6			
Novavax		0		
Unknown	1095	1		
Moderna	34548 2			
Janssen		5		
Emergen	1	0		
Underlying Conditions				
Yes		5		
No	109366 8	5		

## Table 1: Population Characteristics of COVID-19 Breakthrough Cases

## Table 2: Breakthrough Case Rates

Fully Vaccinated Population*	Vaccinated Cases	Unvaccinated Population	Unvaccinated Cases	Vaccinated Case Rate per 100K population	Unvaccinated Case Rate per 100K population
866815	128656	1451359	467232	14842	32193



	Over	
	Ν	
All	3275	100
Age (in years)		
5-11	5	
12-17	19	1
18-24	31	1
25-49	337	
50-64	566	
65+	2317	71
Gender		
Male	1774	54
Female	1497	46
Unknown	4	C
Race/Ethnicity		
Hispanic	407	12
White	1905	58
Black	369	11
API	323	10
AEA	15	C
Other	98	
Unknown	158	5
Travel History		
Yes	140	4
No	1700	52
Unknown	1435	44
Death		
Yes	827	25
No	586	18
Unknown	1862	57
Vaccine Type		
Pfizer	1908	58
Unknown	81	2
Moderna	1043	32
Janssen	243	7
Underlying Conditions		
Yes	2367	72
Νο	908	28

## Table 3: Population Characteristics of COVID-19 Breakthrough Hospitalizations



	Overa	a//
	N	%
All	1180 1	00
Age (in years)		
25-49	36	3
50-64	140	12
65+	1004	85
Gender		
Male	711	60
Female	469	40
Race/Ethnicity		
Hispanic	130	11
White	794	67
Black	122	10
API	113	10
AEA	6	1
Other	10	1
Unknown	5	С
Hospitalization		
Yes	827	70
No	76	6
Unknown	277	23
Vaccine Type		
Pfizer	647	55
Unknown	27	2
Moderna	385	33
Janssen	121	10
Underlying Conditions		
Yes	679	58
No	501	42

## Table 4: Population Characteristics of COVID-19 Breakthrough Deaths

## **Table 5: Breakthrough Death Rates**

Fully Vaccinated	Vaccinated	Unvaccinated	Unvaccinated	Vaccinated Death Rate per 100K population	Unvaccinated Death Rate
Population	Deaths	Population	Deaths		per 100K population
866815	1180	1451359	8068	136	556

\* Please note that the numbers reported for fully vaccinated in the above table may not reflect the total number of completed doses reported on the SNHD dashboard. The CDC considers people to be fully vaccinated 2 weeks after their second dose in a 2-dose series, such as the Pfizer or Moderna vaccines, or 2 weeks after a single-dose vaccine, such as Johnson & Johnson & Johnson vaccine.



Variable	Outcome	Ν	%
Underlying Medical Condition	Yes	2367	72
	No	908	28
Hypertension	Yes	1509	N/A
Immunocompromised	Yes	133	N/A
Chronic Heart Disease	Yes	716	N/A
Chronic Liver Disease	Yes	62	N/A
Chronic Kidney Disease	Yes	471	N/A
Diabetes	Yes	884	N/A
Neurologic/Neurodevelopmental	Yes	197	N/A
Chronic Lung Disease	Yes	627	N/A
Historically Healthy	Yes	290	N/A

## Table 6:Breakdown of COVID-19 Breakthrough Hospitalizations according to Underlying conditions

## Table 7:Breakdown of COVID-19 Breakthrough Deaths according to Underlying conditions

Variable	Outcome	Ν	%
Underlying Medical Condition	Yes	679	58
	No	501	42
Hypertension	Yes	435	N/A
Immunocompromised	Yes	50	N/A
Chronic Heart Disease	Yes	243	N/A
Chronic Liver Disease	Yes	24	N/A
Chronic Kidney Disease	Yes	188	N/A
Diabetes	Yes	259	N/A
Neurologic/Neurodevelopmental	Yes	60	N/A
Chronic Lung Disease	Yes	196	N/A
Historically Healthy	Yes	26	N/A

Notes:

\* White, Black, Asian, and AEA are non-Hispanic.AEA=American Indian/Eskimos/Alaskan Natives & API=Asian Pacific Islander

\* The report does not include breakthrough hospitalizations from State approved facilities as State is responsible for their investigation.

\* The breakdown of underlying conditions are not mutually exlusive (i.e., a person can have more than one risk factor).